OncoMatch/Clinical Trials/NCT06147570
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Is NCT06147570 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HS-10365 capsules for nonsmall cell lung cancer.
Treatment: HS-10365 capsules — HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: RET fusion
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: selective RET inhibitor
Previous or current treatment with selective RET inhibitors
Cannot have received: multi-kinase inhibitor of RET
Previous or current treatment with ... multi-kinase Inhibitor of RET
Cannot have received: systemic therapy
Exception: adjuvant/neoadjuvant therapy completed at least 6 months prior to relapse
Prior systemic therapy for metastatic disease. Treatment (including chemotherapy or immunotherapy) in the adjuvant/neoadjuvant setting is permitted if it was completed at least 6 months prior to relapse.
Lab requirements
Blood counts
adequate bone marrow reserve required
Inadequate bone marrow reserve or serious organ dysfunction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify